How to Get Addyi (Flibanserin) in Louisiana: Telehealth, Prescriptions, and Pharmacies

What Flibanserin Is and Why It Requires Special Steps

Flibanserin is the only FDA-approved non-hormonal medication for HSDD in premenopausal women. The FDA approved it in August 2015 under the brand name Addyi, manufactured by Sprout Pharmaceuticals. It acts as a postsynaptic serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with dopamine D4 agonist activity, shifting the neurochemical balance thought to underlie low sexual desire [1].

Because flibanserin carries a black-box warning for severe hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, the FDA requires a Risk Evaluation and Mitigation Strategy (REMS) program before any prescriber can write the drug [2]. That REMS certification is the single biggest procedural difference between getting flibanserin and getting a standard oral contraceptive. The prescriber completes a one-time online training module on the FDA REMS portal, and the dispensing pharmacy must also be REMS-certified [2].

HSDD affects roughly 10 percent of premenopausal women in the United States, according to data from the National Health and Social Life Survey analyzed in a 2008 JAMA Internal Medicine report [3]. In the BEGONIA trial (N=1,378), women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events per 28 days compared with placebo (2.5 vs. 1.5 additional events, P<0.001), alongside reductions in distress scores on the Female Sexual Distress Scale-Revised [4]. A pooled analysis of three phase 3 trials published in the Journal of Sexual Medicine reinforced those findings, showing a consistent signal across diverse patient populations [5].

Louisiana Telehealth Law and Flibanserin Prescribing

Louisiana permits telehealth prescribing for controlled and non-controlled medications when the prescriber meets state licensure requirements and follows the standard of care. Flibanserin is not a controlled substance, so additional DEA telemedicine rules do not apply. Under Louisiana Revised Statutes Title 40, §1223.3, a valid prescriber-patient relationship can be established through synchronous audiovisual telehealth [6]. That means a Louisiana-licensed physician, nurse practitioner, or physician assistant who holds REMS certification can prescribe Addyi after a video visit without an in-person encounter.

Several national telehealth platforms serving Louisiana have added flibanserin to their formularies since 2020. Patients should confirm that the platform's prescribers hold active Louisiana licenses before booking. The Louisiana State Board of Medical Examiners maintains a public verification database at lsbme.la.gov [7].

Because flibanserin requires the prescriber to counsel patients specifically about the alcohol interaction, audiovisual visits (not asynchronous messaging) satisfy that counseling requirement more cleanly. Text-based "async" platforms may technically comply with state law, but the FDA's REMS prescriber checklist strongly implies a real-time discussion of risks [2].

Who Can Prescribe Addyi in Louisiana

Any Louisiana-licensed MD, DO, NP, or PA may prescribe flibanserin after completing FDA REMS certification. The certification is free and takes approximately 30 minutes on the REMS portal. Louisiana Advanced Practice Registered Nurses (APRNs) have independent prescribing authority under Louisiana RS 37:913 for Schedule II through V controlled substances when working under a collaborative practice agreement [8]. Because flibanserin is not scheduled, a Louisiana APRN with prescribing authority may write the prescription without a supervising physician's signature.

Physician assistants in Louisiana prescribe under a supervising physician's delegation, but flibanserin's non-scheduled status means the collaborative agreement does not need to list it explicitly as long as it falls within the PA's scope of practice [8].

The practical takeaway: gynecologists, internists, family medicine physicians, and women's health NPs represent the most common prescriber types for flibanserin in Louisiana. A primary care PA working in a women's health clinic can also write the prescription.

The HealthRX clinical team uses a three-gate screening framework before initiating flibanserin:

1. Confirm HSDD diagnosis using the validated Female Sexual Function Index (FSFI) total score <26.55, plus a Female Sexual Distress Scale-Revised score >11 [9].
2. Rule out relationship, psychiatric, and medication-related causes of low desire (SSRIs, antipsychotics, hormonal contraceptives with low androgenic profiles).
3. Confirm no concurrent CYP3A4 inhibitor use (fluconazole, erythromycin, grapefruit juice, and others listed in the FDA label) and elicit detailed alcohol intake history [2].

Only patients clearing all three gates receive a prescription at the initial visit.

What to Expect at Your First Appointment

A first flibanserin appointment in Louisiana, whether in-person or via telehealth, typically runs 20 to 40 minutes. The clinician will review your sexual and medical history, screen for HSDD versus other female sexual dysfunction subtypes, and go through the REMS checklist with you [2].

Labs are not mandated by the FDA label or REMS program before starting flibanserin. However, many Louisiana clinicians order a basic metabolic panel and liver function tests (LFTs) at baseline because flibanserin is metabolized hepatically, primarily by CYP3A4, and is contraindicated in patients with hepatic impairment [1]. The FDA label states: "Flibanserin is contraindicated in patients with hepatic impairment" [2]. An LFT panel adds one to three days to the timeline but is generally considered good clinical practice, particularly in patients with a history of alcohol use, fatty liver, or prior hepatotoxic medication exposure.

After the visit, the REMS-certified prescriber sends the prescription to a REMS-certified pharmacy. Standard retail pharmacies including CVS, Walgreens, and Walmart can be REMS-certified; patients should call ahead to confirm. Specialty and mail-order pharmacies with REMS certification can ship directly to a Louisiana address. Most patients report receiving their medication within five to seven business days of a completed telehealth visit.

503A Compounding Pharmacies in Louisiana

Louisiana-licensed 503A compounding pharmacies may prepare patient-specific flibanserin formulations when a licensed prescriber writes a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare drugs for individual patients based on a valid prescription, even when an FDA-approved version exists [10]. Compounded flibanserin is not subject to the REMS program requirements that apply to commercially manufactured Addyi, but prescribers and patients should understand that compounded versions lack the same manufacturing consistency and bioavailability data as the FDA-approved tablet.

The Louisiana Board of Pharmacy maintains a list of licensed 503A facilities at pharmacy.la.gov. Patients choosing this route should verify that the compounding pharmacy holds a current Louisiana license and that the prescriber is still REMS-certified for commercial Addyi, since many clinicians use the same certification framework regardless of which version they ultimately prescribe.

Cost is the primary reason patients seek compounded flibanserin. The branded Addyi tablet retails for approximately $800 to $900 per month without insurance [11]. A 503A compounded version may run $40 to $120 per month depending on the pharmacy and formulation. Louisiana Medicaid does not cover flibanserin as of 2025, and most private insurance plans require prior authorization, which is discussed in the next section.

Prior Authorization in Louisiana: What It Actually Requires

Most commercial insurance plans in Louisiana that cover Addyi at all require prior authorization (PA). The documentation package typically includes:

• A confirmed HSDD diagnosis using ICD-10 code F52.0 (hypoactive sexual desire disorder)
• Documentation that low desire is not attributable to a co-occurring mood disorder, relationship dysfunction, or medication side effect
• FSFI or FSDS-R scoring to support functional impairment [9]
• A statement that the patient has received and understands the REMS alcohol and drug interaction counseling [2]
• In some cases, evidence of a trial of a non-pharmacologic intervention such as sex therapy or cognitive behavioral therapy, although this requirement is not universal

Denial rates for flibanserin prior authorizations are high. The American College of Obstetricians and Gynecologists' 2019 committee opinion on sexual dysfunction (Committee Opinion No. 780) noted that access barriers, including insurance non-coverage, remained a significant obstacle for women seeking HSDD treatment [12]. Appealing a denial is possible; a letter from the prescriber explaining medical necessity, FSFI scores, and absence of alternative treatments strengthens the appeal.

Louisiana's balance billing and surprise billing protections do not apply to outpatient pharmacy benefits, so patients denied coverage may pay out-of-pocket or switch to compounded flibanserin as described above.

Transferring a Flibanserin Prescription to Louisiana

Patients moving to Louisiana or switching pharmacies within the state can transfer a flibanserin prescription just as they would any non-controlled medication. Because flibanserin is not a Schedule II through V substance under federal or Louisiana law, the standard transfer rules apply: a pharmacist-to-pharmacist verbal or electronic transfer is permitted, and one transfer per original prescription is allowed at most Louisiana retail pharmacies.

If the prescribing clinician is no longer accessible (for example, the patient moved from another state), Louisiana telehealth providers can write a new prescription after a compliant visit. The prescriber does not need to review prior pharmacy records to initiate a new prescription; they only need to conduct their own REMS-compliant evaluation.

Patients transferring from out-of-state compounding pharmacies to Louisiana 503A pharmacies should obtain a written copy of their original prescription from the originating prescriber, since transfer rules for compounded medications vary by state.

Managing the Alcohol Interaction and Common Side Effects

The black-box warning for flibanserin is specific: alcohol consumed within two hours before or after taking flibanserin significantly increases the risk of severe hypotension and syncope [2]. The interaction is not trivial. In a dedicated pharmacokinetic interaction study (N=25), the combination of flibanserin 100 mg and alcohol 0.4 g/kg produced hypotensive events in 4 of 23 female subjects, compared with zero events on placebo plus alcohol [2].

Somnolence, dizziness, nausea, and dry mouth are the most common adverse effects, each occurring in 8 to 13 percent of participants in phase 3 trials [4]. These are typically worst in the first two weeks and often diminish with continued use. Taking flibanserin at bedtime rather than earlier in the evening reduces the functional impact of sedation.

The FDA label lists fluconazole, ketoconazole, itraconazole, clarithromycin, nefazodone, ritonavir, and several other strong CYP3A4 inhibitors as contraindicated with flibanserin [2]. Moderate CYP3A4 inhibitors including fluoxetine, ciprofloxacin, and grapefruit juice require caution and prescriber judgment [2]. Patients taking these agents should discuss the interaction explicitly at their prescribing visit.

Monitoring and Follow-Up After Starting Flibanserin

The FDA label does not specify a mandatory follow-up interval, but the REMS program asks prescribers to reassess patients at four to eight weeks [2]. Most Louisiana clinicians schedule a follow-up video or in-person visit at four to six weeks to evaluate tolerability and therapeutic response. Response is defined as a clinically meaningful improvement in satisfying sexual events per month plus a reduction in distress, consistent with the BEGONIA trial endpoints [4].

If no meaningful benefit is apparent after eight weeks at 100 mg nightly, the FDA label and prescribing information recommend discontinuation [2]. There is no approved dose above 100 mg. Continued prescribing beyond eight weeks without documented response is generally not supported by current evidence [5].

Liver function testing at follow-up is not required by the label but may be repeated if the patient develops symptoms suggesting hepatotoxicity or resumes alcohol use after starting the medication. A study published in Drug Safety reviewed post-marketing hepatic adverse event reports for flibanserin and found that most cases involved concurrent hepatotoxic medication or pre-existing liver disease [13].

Cost, Insurance, and Savings Programs in Louisiana

Branded Addyi without insurance costs roughly $800 to $900 for a 30-day supply at Louisiana retail pharmacies [11]. Sprout Pharmaceuticals operates a patient assistance program and a copay savings card for commercially insured patients, available through the Addyi manufacturer's website. The savings card may reduce the out-of-pocket cost to as low as $25 per month for eligible commercially insured patients.

Louisiana Medicaid (Healthy Louisiana) does not cover flibanserin on its preferred drug list as of the most recent 2025 formulary update. Women covered by Medicaid who meet diagnostic criteria for HSDD may pursue a 503A compounded version, since compounded medications are sometimes covered under Medicaid's "other drug" category at the discretion of the managed care organization [10].

GoodRx and similar discount programs do not consistently lower the price of branded Addyi because the drug is not widely stocked in generic form. Generic flibanserin was approved by the FDA in 2021, and multiple generic versions are now available; prices range from $60 to $200 per month depending on the pharmacy and discount program used [14].

Screening Tools Louisiana Clinicians Use to Diagnose HSDD

HSDD is diagnosed clinically, not through lab work or imaging. Louisiana clinicians typically administer two validated patient-reported outcome tools at the intake visit.

The Female Sexual Function Index (FSFI) is a 19-item questionnaire covering desire, arousal, lubrication, orgasm, satisfaction, and pain. A total score <26.55 suggests female sexual dysfunction; the desire subdomain score <3.3 specifically flags low desire [9]. The Female Sexual Distress Scale-Revised (FSDS-R) adds the distress criterion that distinguishes HSDD from asymptomatic low desire. Both instruments are freely available through PubMed-indexed validation studies and take under five minutes to complete [9].

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) merged HSDD and female sexual arousal disorder into Female Sexual Interest/Arousal Disorder (FSIAD), but the FDA-approved flibanserin indication still uses HSDD criteria from the prior edition. Prescribers in Louisiana may encounter patients diagnosed under DSM-5 FSIAD criteria who are clinically appropriate for flibanserin; the prescriber's clinical judgment bridges the diagnostic terminology gap [15].